SCHEMBL6371692

SCHEMBL6371692

C=C1/C(=C\C=C2CCC[C@@]3(C)C2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)[C@@H](CCCCCO)[C@H]1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VDR P11473 16/20 0.76
▸ MAPT P10636 3/20 0.69
▸ SMN1; SMN2 Q16637 2/20 0.69
▸ NR1I2 O75469 1/20 0.69
▸ ABCB11 O95342 1/20 0.69
▸ GC P02774 1/20 0.69
▸ PGR P06401 1/20 0.69
▸ ADORA3 P0DMS8 1/20 0.69
▸ RXRA P19793 1/20 0.69
▸ CHRM3 P20309 1/20 0.69
▸ CNR1 P21554 1/20 0.69
▸ SLC6A2 P23975 1/20 0.69
▸ HTR2C P28335 1/20 0.69
▸ MAPK1 P28482 1/20 0.69
▸ AGTR1 P30556 1/20 0.69
▸ SLC6A4 P31645 1/20 0.69
▸ ADRA1A P35348 1/20 0.69
▸ PTGS2 P35354 1/20 0.69
▸ OPRD1 P41143 1/20 0.69
▸ OPRK1 P41145 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8003751 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL8012877 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL6370883 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL8003748 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL8012881 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL8019534 0.99 VDR (0.77) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL8019537 0.99 VDR (0.77) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL6365594 0.99 VDR (0.77) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL14278413 0.99 VDR (0.77) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL3161619 0.99 VDR (0.77) VDRMAPTSMN1; SMN2NR1I2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113349-A1 2-Alpha vitamin D derivatives having substituents HIROAKI TAKAYAMA (JP) 2005-05-26 — — US disclosed
EP-1219599-A1 VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2 ALPHA-POSITION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-07-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113349-A1 2-Alpha vitamin D derivatives having substituents CYP24A1, CYP2R1, VDR VDR 3/4885MAPT 4882/4885SMN1; SMN2 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback